Skip to main content

Table 2 pCR analyses in the PP and ITT populations

From: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

  TA4415V (N = 54) Reference trastuzumab (N = 54) Difference (95% CI)
Per-Protocol Populationa
pCR 18 (37.50) 15 (34.09) −0.03 (− 0.23, 0.16)
Intention-to-treat Population
pCRb 19 (37.25) 16 (34.78) −0.02 (− 0.22, 0.17)
pCRc (Imputed analysis) 19 (35.19) 16 (29.63) −0.05 (− 0.23, 0.12)
  1. Data are n (%), unless otherwise indicated
  2. Difference = proportion (reference trastuzumab) – proportion (TA4415V)
  3. an = 48 for TA4415V and n = 44 for reference trastuzumab
  4. bn = 51 for TA4415V and 46 for reference trastuzumab
  5. cn = 54 for TA4415V and 54 for reference trastuzumab